等待開盤 09-05 09:30:00 美东时间
0.000
0.00%
With experienced commercial team in place, Ionis poised to independently bring steady cadence of potentially transformational RNA-targeted medicines to patients beginning in 2024 Plan to add...
2023-10-04 19:00
Reported Phase 3 data showing eplontersen continued to show improvement in ATTRv-PN through 85 weeks; December 22, 2023 PDUFA date Completed enrollment in donidalorsen OASIS-HAE study and ep...
2023-08-09 19:00